Prevtec Microbia completes a $4.7 million round of financing 2015

Prevtec Microbia completes a $4.7 million round of financing
2015 should be a pivotal year with EU Commercial Launch of swine vaccine
Montreal, Quebec, March 11, 2015 – Prevtec Microbia (“Prevtec”) is pleased to
announce that it has successfully completed a 2014/2015 round of financing for $4.7
million. Up to 36% of the funds were provided by current shareholders, amongst them,
Telesystem Ltd, Groupe Jafaco Gestion Inc., and Desjardins-Innovatech,S.E.C.
The remaining 64% of the funds, $3 million, was provided by VVC, a Canadian-based
venture capital fund investing globally with a singular focus on animal health. VVC seeks
above-market returns by identifying compelling opportunities and providing intellectual
and financial capital, operational expertise and a rich network that helps build successful
businesses and technologies.
“We wish to thank our long-time shareholders for their support in this key phase of our
Company’s commercial development and welcome our new investor. Our mission is to
bring multiple innovative products to market in the coming years and collaborate
efficiently with our key partners,” said Michel Fortin, President and CEO of Prevtec
Pending market authorization, Prevtec anticipates the commercial launch of its live
bacterial swine vaccine Coliprotec®F4 in many countries of the European Union over the
course of 2015. Prevtec’s oral vaccine immunizes swine against enterotoxigenic F4positive E. coli, thus improving animal health.
Prevtec has secured a distribution agreement with Elanco, a world leader in animal
health, for the commercialization of Coliprotec®F4 in the European Union.
About Prevtec Microbia
Prevtec Microbia is a private Canadian biotechnology company developing innovative
biological products for the prevention of diseases in food-animals. The Company’s
mission is to develop technologies that improve animal health, contributing in better
ways to feed the planet.
Since 2008, Prevtec Microbia has sold its first commercial product, Coliprotec®F4, an
E.coli vaccine for swine, in Canada. The product is also registered in Brazil and other
countries. In early January 2015, the European Committee for Medicinal Products for
Veterinary Use issued a positive opinion recommending the granting of a market
Prevtec microbia Inc.
Head Office
1250 Rene-Levesque Blvd. W.
Suite 3800
Montreal (Quebec)
H3B 4W8 Canada
T 514.905.0401
“A better way to feed the planet"
R&D and Operations
3395 Casavant Blvd. W.
Saint-Hyacinthe (Quebec)
J2S 0B8 Canada
T 450.774.7000
F 450.774.8777
authorization in the European Union for Coliprotec®F4. See more information at
30 -
Michel Fortin
President CEO
+1 514-905-0401
[email protected]
Christian Roy, CPA, CA
Finance Manager
+1 514-905-0401
[email protected]
Dr. Paul Dick
Managing Director
[email protected]
+1 519 546-8427
Prevtec microbia Inc.
“A better way to feed the planet"
p. 2